Drug recall · March 11, 2020
Mesalamine Delayed-Release Tablets recall
Why: Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Mesalamine Delayed-Release Tablets, USP, 1.2 gram, 120-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054; NDC 0591-2245-22.
- Lots / codes
Lot #: 1342500A, Exp 10/2020
- Quantity
- 3,695 bottles
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Nationwide in the USA.
- Initiated
- February 20, 2020 · Voluntary: Firm initiated
- Classified
- March 2, 2020
- Reported
- March 11, 2020
- Ended
- October 6, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Mesalamine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.